Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Genomic decoding of drug-resistant tuberculosis transmission in Thailand over three decades.
Thawong, N; Srilohasin, P; PHELAN, JE; Phornsiricharoenphant, W; Tongsima, S; Suriyaphol, P; Prammananan, T; Faksri, K; Sawaengdee, W; Wang, L; Hinthong, W; HIBBERD, ML; CAMPINO, S; Wattanapokayakit, S; Mahasirimongkol, S; Chaiprasert, A; CLARK, TG;
2025
Scientific reports, (2025).15 1 10.1038/s41598-025-15093-7.
Risk of relapse: TB treatment outcome associates with differentially culturable <i>M. tuberculosis</i> counts in sputum samples.
Decker, J; Mukamolova, GV; Garton, N; GRINT, DJ; Barer, MR;
2025
IJTLD open, (2025).2 8 10.5588/ijtldopen.25.0085.
The potential impact of reduced international donor funding on the household economic burden of tuberculosis in low- and middle-income countries.
Portnoy, A; CLARK, R; Jit, M; MCQUAID, F; Richards, A; Bakker, R; Sumner, T; Prŷs-Jones, T; HOUBEN, RM G J; WHITE, R; HORTON, K; Menzies, N;
2025
medRxiv (2025). 10.1101/2025.08.09.25333356.
Multimorbidity in tuberculosis-affected households. Evaluation of disease clustering and the acceptability and yield of integrated health screening in east and southern Africa.
CALDERWOOD, CJ;
2025
(2025). 10.17037/PUBS.04677404.
Adverse drug reactions, particularly liver disorders, drive interruptions in anti-tuberculosis treatment: A retrospective cohort study.
Dixon, EG; Biraua, E; Brencsēns, E; Pašuks, V; Riekstina, V; Šperberga, A; Muckian, MD; Dear, JW; Kuksa, L; Sloan, DJ; STAGG, HR;
2025
British journal of clinical pharmacology, (2025).91 12 10.1002/bcp.70197.
Authors' Response to "TB Prevalence in People Tested is a Strong Predictor of Xpert Specificity in Community and Risk Group Screening".
Veeken, LD; HORTON, KC; HOUBEN, RM G J;
2025
The Journal of infectious diseases, (2025).232 6 10.1093/infdis/jiaf419.
Tuberculosis Prevalence in People Tested Is a Strong Predictor of Xpert Specificity in Community and Risk Group Screening.
MCCREESH, N; GOVENDER, I; GRANT, AD; KHAN, PY;
2025
The Journal of Infectious Diseases, (2025).232 6 10.1093/infdis/jiaf418.
Temporal complexity in missed doses of rifampicin-sensitive anti-tuberculosis treatment: a prospective cohort study in Tanzania.
Tuwabunze, L; Msaji, KS; Liyoyo, A; PAUL, P; Mpagama, S; STAGG, HR;
2025
BMJ open respiratory research, (2025).12 1 10.1136/bmjresp-2024-003088.
Engagement With Digital Adherence Technologies as Measures of Intervention Fidelity Among Adults With Drug-Susceptible Tuberculosis and Health Care Providers: Descriptive Analysis Using Data From Cluster-Randomized Trials in Five Countries.
Alacapa, J; TADESSE, AW; Deyanova, N; Dube, T; Mganga, A; Powers, R; Van Rest, J; Madden, N; Efo, E; Charalambous, S; Van Kalmthout, K; Jerene, D; FIELDING, K;
2025
JMIR public health and surveillance, (2025).11, 10.2196/62881.
A timeline of reckoning: Tracking the historical rise of antimicrobial resistance across HIV, TB, and malaria.
Williamson, T; Adderley, J; Quinn, K; CLARK, TG; Lewin, SR; Doerig, C;
2025
Journal of global antimicrobial resistance, (2025).44, 10.1016/j.jgar.2025.07.014.